Spots Global Cancer Trial Database for A Study of CriPec® Docetaxel Given to Patients With Solid Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of CriPec® Docetaxel Given to Patients With Solid Tumours
Official Title: A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec® Docetaxel in Patients With Solid Tumours
Study ID: NCT02442531
Interventions
Study Description
Brief Summary: The goal of this Phase1 clinical research study is to find the highest safe dose of CriPec® docetaxel that can be given in the treatment of patients with solid tumours.
Detailed Description: The study is designed to explore the safety, tolerability, pharmacokinetics and pharmacodynamics of CriPec® docetaxel and to identify the Maximum Tolerated Dose (MTD).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Hospital Leuven, Leuven, , Belgium
VUMC Amsterdam, Amsterdam, , Netherlands
UMC Groningen, Groningen, , Netherlands
Erasmus Medical Center, Rotterdam, , Netherlands
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
